Finance

Lists
Why is AIM down 3,33%?
Dive Deeper
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
USD 0,12
-3,33%
(-0,0040) 1D
20 Nov., 13:19:54 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AIM...
Open
USD 0,12
High
USD 0,13
Low
USD 0,12
Mkt. cap
4,63 m.
Avg. vol.
541,66 k
Volume
735,58 k
52-wk high
USD 1,88
52-wk low
USD 0,12
EPS
-USD 2,46
Beta
1,32
Shares outstanding
39,92 m.
No. of employees
20
Open
USD 0,12
High
USD 0,13
Low
USD 0,12
Mkt. cap
4,63 m.
Avg. vol.
541,66 k
Volume
735,58 k
52-wk high
USD 1,88
52-wk low
USD 0,12
EPS
-USD 2,46
Beta
1,32
Shares outstanding
39,92 m.
No. of employees
20
News stories
From web sources and news partners
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersPhiladelphia, Pennsilvanië, Verenigde State van Amerika
SectorHealth Care
Industry-
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
21,00 k
22,00 k
26,00 k
22,00 k
Cost of goods sold
40,00 k
4,00 k
5,00 k
7,00 k
Cost of revenue
40,00 k
4,00 k
5,00 k
7,00 k
Research and development expenses
999,00 k
381,00 k
589,00 k
846,00 k
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,93 m.
1,86 m.
2,94 m.
2,13 m.
Operating expense
2,93 m.
2,24 m.
3,53 m.
2,97 m.
Total operating expenses
2,97 m.
2,25 m.
3,54 m.
2,98 m.
Operating income
-2,95 m.
-2,23 m.
-3,51 m.
-2,96 m.
Other non operating income
-942,00 k
-500,00 k
-
74,00 k
EBT including unusual items
-4,18 m.
-3,02 m.
-3,79 m.
-3,14 m.
EBT excluding unusual items
-4,18 m.
-3,02 m.
-3,79 m.
-3,14 m.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4,18 m.
-3,02 m.
-3,79 m.
-3,14 m.
Net profit margin
-19 880,95%
-13 740,91%
-14 569,23%
-14 286,36%
Earnings per share
-0,44
-0,69
-0,43
-0,21
Interest and investment income
110,00 k
8,00 k
21,00 k
-
Interest expense
-391,00 k
-304,00 k
-295,00 k
-259,00 k
Net interest expenses
-281,00 k
-296,00 k
-274,00 k
-259,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,91 m.
-2,18 m.
-2,98 m.
-2,68 m.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme